Physician profile
Kevin Park
NPI 1063441491
$3,252.10
in general payments reported to CMS, 2019-2025
22 companies · $764 in 2025
The $764 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $848 · 2020: $103 · 2022: $423 · 2023: $516 · 2024: $598 · 2025: $764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,878.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,878.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $778.38 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $614.11 | 2022-2025 | |
| Novo Nordisk INC | $424.85 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $241.04 | 2022-2025 | |
| Pfizer INC. | $195.92 | 2019-2024 | |
| Amgen INC. | $168.84 | 2019-2025 | Evenity, Repatha, Otezla |
| Lilly USA, LLC | $126.59 | 2022-2025 | Zepbound, Mounjaro |
| Janssen Pharmaceuticals, INC | $119.02 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.21 | 2019-2022 | |
| Glaxosmithkline, LLC. | $86.63 | 2019-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $78.02 | 2019 | |
| Novartis Pharmaceuticals Corporation | $59.01 | 2019-2022 | |
| Corium, LLC | $41.09 | 2023-2025 | Azstarys |
| Indivior INC. | $35.19 | 2024 | Sublocade |
| Axsome Therapeutics, INC. | $34.48 | 2024 | Auvelity |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $29.51 | 2019-2024 | Gardasil, Vaxelis, Gardasil 9 |
| Kowa Pharmaceuticals America, INC. | $26.87 | 2019-2022 | |
| Inspire Medical Systems, INC. | $25.16 | 2024 | Inspire |
| Tris Pharma INC | $17.00 | 2025 | Dyanavel Xr |
| Aimmune Therapeutics, INC. | $14.23 | 2025 | Vowst |
| Exact Sciences Corporation | $14.15 | 2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $12.80 | 2023 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.